In summary, first, the lack of PPAR-γ activity in RA and SLE was proven in vitro and in vivo models, minimizing the ability of TNF-α and IL-6 to downregulate adiponectin levels via this pathway. The gene discussed is PPARG; the disease is rheumatoid arthritis.